Data: 08/08/2026
Total encontrado: 6
1/6US=94 / Biol/Mol
Matthews DJ, Gerritsen ME. Cell cycle control. In: ___. Targeting protein kinases for cancer therapy. New Jersey: Wiley, 2010. p. 327-90. ISBN 978-0-470-22965-1.

CICLO CELULAR; QUINASES CICLICAS DEPENDENTES (CDK); CDK4; CDK6; CDK2; CDK3; CDK1; CDK10; CCRK; CDCH; PRODUCAO DE MRNA; CDK7; CDK8; CDK9; CDK11; CDK12; CDK13; CDK5; QUINASE CICLINA G-ASSOCIADOS (GAK); QUINASES MITOTICAS; QUINASE POLO-LIKE (PLK); AURORA-QUINASE; ATAXIA-TELANGIECTASIA MUTADO (ATM); ATAXIA TELANGIECTASIA E PROTEINA RAD3 RELACIONADOS (ATR); CHK1; CHK2; MAPKAPK2

2/6US=94 / Biol/Mol
Matthews DJ, Gerritsen ME. Structural biochemistry of kinase inhibitors. In: ___. Targeting protein kinases for cancer therapy. New Jersey: Wiley, 2010. p. 391-434. ISBN 978-0-470-22965-1.

INIBIDORES DE QUINASES; BIOQUIMICA ESTRUTURAL; ESTRATEGIAS INIBIDORAS; ARQUITETURA ATP; INIBIDORES DE CHK1; INIBIDORES DE CDK2; INIBIDORES DA FAMILIA SRC; INIBIDORES DO RECEPTOR EGF; CONFORMACAO INATIVA; INIBICAO NAO-COMPETITIVA

3/6US=85 / Biol/Mol
Wandl S, Wesierska-Gadek J. Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 242-9. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5.

CDKS; G1; FARMACOLOGICA CDK2 INIBIDOR; G1 PRISAO; PARADA DO CICLO CELULAR; SUPRESSOR DE TUMOR P53; APOPTOSE

4/6US=85 / Biol/Mol
Wandl S, Wesierska-Gadek J. Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 242-9. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5.

CDKS; FARMACOLOGICA CDK2 INIBIDOR; SUPRESSOR DE TUMOR P53; APOPTOSE; PRIVACAO DE SORO; PARADA DO CICLO CELULAR

5/6US=67 / Biol/Mol
Knights CD, Pestell RG. The cell cycle: therapeutic targeting of cell regulatory components and effector pathways in cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 3-32. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CICLO CELULAR; SEGMENTACAO TERAPEUTICA; COMPONENTES CELULARES; VIAS REGULADORAS; CANCER; CICLINA DEPENDENTE DE QUINASE; INIBIDORES CDK; TERAPIA; ACETILACAO; P53; CICLINA D1; EGFR; HDAC; STI-571; FLAVOPIRIDOL; INIBIDOR CDK2

6/6US=671 / Tese/FAP
Lima Junior CLH. Estudo da expressão imunoistoquímica de ciclina D1, CDK4, ciclina e, CDK2 e estudo da hibridização “in situ” por fluorescência para ciclina D1 em melanoma cutâneo primário de pacientes submetidos à pesquisa de linfonodo sentinela. [Study of the expression of cyclin D1, CDK4, cyclin E and, CDK2 by immunohistochemistry and study of fluorescent in situ hybridization (FISH) for cyclin D1 in primary cutaneous melanoma of patients submitted to sentinel lymph node biopsy]. São Paulo, 2017. 71 p. Tese(Doutorado)-Fundação Antônio Prudente.

Disponível em: http://accamargo.phlnet.com.br/Doutorado/2017/CristianoHorta/CristianoHorta.pdf

Curriculum Lattes

MELANOMA; BIOPSIA DE LINFONODO SENTINELA; IMUNO-HISTOQUIMICA; CICLINA D1; CICLINA E; QUINASES CICLINA-DEPENDENTES; HIBRIDIZACAO IN SITU FLUORESCENTE; ANALISE SERIAL DE TECIDOS